Link Health Pharma

Guangzhou Link Health Pharma Co., Ltd. was founded in 2012 as a research-oriented enterprise focused on the cooperation and introduction of globally innovative pharmaceutical products and technologies, as well as the development of new drugs targeting novel mechanisms. Since its inception, the company has adhered to an international path of pharmaceutical innovation, striving to meet the clinical needs of Chinese patients and improve their quality of life. Developing innovative drugs that align with China’s national conditions remains the company's unwavering mission.Established by overseas returnees and domestic pharmaceutical industry elites, the company has evolved from initial exploratory models to integrating global resources for technology acquisition. From signing its first new drug collaboration agreement to the anticipated launch of its first product in 2019, over six years Link Health Pharma has consistently upheld "innovation-driven" growth. The company leads in researching multiple novel targets, both within China and globally, continuously optimizing collaboration models and enhancing clinical development efficiency, gradually becoming a pioneer in new drug applications and development in South China. Link Health Pharma has been honored as a leading enterprise in the Guangzhou Development Zone, ranked among the top 50 biotech innovators in the Guangdong-Hong Kong-Macao Greater Bay Area in 2018, and recognized as a National High-Tech Enterprise.Currently, the company's R&D pipeline includes 12 new drug projects, covering major chronic diseases such as oncology and gastroenterology, as well as specialty diseases related to aging, such as orthopedics and ophthalmology. Among these, one product has been launched, while seven are in clinical stages. The company’s research and clinical teams possess extensive experience in drug development. Since 2015, the company has successfully advanced four Class 1 new drug clinical trial applications and one marketing application. It holds 22 invention patents, including 13 authorized patents and one PCT patent.